OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial Carcinoma

May 31st 2023

Andrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma

Dr Wise on the Deciding Between Doublet and Triplet Regimens in Prostate Cancer

May 31st 2023

David R. Wise, MD, PhD, discusses considerations for the use of doublet or triplet regimens for the treatment of patients with prostate cancer.

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

May 31st 2023

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate Cancer

May 31st 2023

Benjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

May 31st 2023

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Dr Katims on the Goal for Investigating the Immune Phenotype of FGFR3+ Upper Tract Urothelial Carcinoma

May 30th 2023

Andrew Katims, MD, MPH, discusses the rationale for investigating immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing.

Dr Santos on the Impact of Cemiplimab With Chemotherapy in Squamous NSCLC

May 30th 2023

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2+ Breast Cancer

May 30th 2023

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial Cancer

May 30th 2023

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC

May 30th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations

May 26th 2023

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

Dr Champ on Boost Radiotherapy in Breast Cancer

May 26th 2023

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Dr Wang on the Future of Targeted Therapies in AML

May 26th 2023

Eunice Wang, MD, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia.

Dr Park on the Role of Radiation Therapy in NSCLC

May 26th 2023

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic Cancer

May 26th 2023

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Dr Zonder on the Real-World Use of Ixazomib-based Therapy in R/R Multiple Myeloma

May 26th 2023

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Dr Bal on the Clinical Implications of Cilta-cel in R/R Multiple Myeloma

May 25th 2023

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Chiang on Frontline Treatment Combinations in ES-SCLC

May 25th 2023

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Dr Omene on Decreasing Disparities in Breast Cancer

May 25th 2023

Coral O. Omene, MD, PhD, discusses the importance of a multidisciplinary, patient-focused approach to mitigating disparities in the care of patients with breast cancer.

Dr Wise on the Optimal Use of Treatment Intensification in mHSPC

May 25th 2023

David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.